Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight

2023-01-09
PRNewswire
临床结果
The dynamics of the rheumatoid arthritis market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Aclaris Therapeutics [Zunsemetinib (ATI-450)], Abivax [ABX464], and others with their key candidates are in the late clinical and filing stage.
LAS VEGAS, Jan. 9, 2023 /PRNewswire/ -- DelveInsight's
Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Rheumatoid Arthritis Market Report
As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately
USD 27 billion in 2021.
According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately
4.
7 million in 2021.
Leading rheumatoid arthritis companies such as
The promising rheumatoid arthritis therapies in the pipeline include
Ozoralizumab (TS-152),
Artlegia (Olokizumab),
Otilimab (GSK3196165/MOR103),
Cevidoplenib (SKI-O-703),
MPC-300-IV,
Rabeximod (Rob 803), and others.
In
June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA.
In
December 2021,
Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research.
Discover which therapies are expected to grab the major rheumatoid arthritis market share @
Rheumatoid Arthritis Market Report
Rheumatoid Arthritis Overview
Rheumatoid arthritis is a type of autoimmune disease. It happens when our immune system, which is supposed to defend us, malfunctions and starts attacking our own tissues. It causes inflammation in the joint lining (the synovium). As a result, joints may become red, warm, swollen, and painful, which are all symptoms of rheumatoid arthritis. The precise causes of rheumatoid arthritis are still unknown.
Because the early signs and symptoms of rheumatoid arthritis are similar to those of many other diseases, it can be difficult to detect in its early stages. There is no single blood test or physical finding that can confirm the diagnosis of rheumatoid arthritis.
There is no known cure for rheumatoid arthritis. However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs).
Rheumatoid Arthritis Epidemiology Segmentation
DelveInsight estimates that there were approximately
4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021.
Among the EU4 and the UK countries, Germany accounted for the highest number of rheumatoid arthritis cases, whereas France accounted for the lowest cases in 2021
The
rheumatoid arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalent Cases
Total Diagnosed Prevalent Cases
Gender-specific Prevalent Cases
Age-specific Prevalent Cases
Severity-specific Prevalent Cases
Patients on Targeted Therapies
Line-Wise Treated Cases
Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends @
Rheumatoid Arthritis Epidemiological Insights
Rheumatoid Arthritis Treatment Market
Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are
Medicine (for long-term relief of symptoms and slowing the progression of the condition),
Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and
Surgery (to correct any joint problems that develop over a period of time).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression.
Moreover, disease-modifying antirheumatic drugs (DMARDs) are used to target inflammation and prevent further joint damage and disease progression. DMARDs are a class of drugs that have been shown to affect the underlying cause of rheumatoid arthritis by reducing immune system overactivity, thereby alleviating pain, swelling, and stiffness and preventing joint changes. DMARDs can be prescribed singly or in combination as an initial part of treatment.
Methotrexate is the first-line DMARD agent for the majority of rheumatoid arthritis patients. It has a relatively quick onset of action at therapeutic doses (6-8 weeks), good efficacy, a low toxicity profile, is easy to administer, and is relatively inexpensive.
To know more about rheumatoid arthritis guidelines, visit @
Rheumatoid Arthritis Management
Rheumatoid Arthritis Pipeline Therapies and Key Companies
Artlegia (Olokizumab): R-Pharm
Otilimab (GSK3196165/MOR103): GlaxoSmithKline
Rabeximod (Rob 803): Cyxone
MBS2320: Istesso
AMT-101: Applied Molecular Transport
Dazodalibep (HZN-4920): Horizon Therapeutics
Cevidoplenib (SKI-O-703): Genosco/Oscotec
HB-AdMSCs: Hope Biosciences
ABX464: Abivax
MPC-300-IV: Mesoblast
Learn more about the FDA-approved drugs for rheumatoid arthritis @
Drugs for Rheumatoid Arthritis Treatment
Rheumatoid Arthritis Market Dynamics
The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the
increasing awareness and
expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as
biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth.
Furthermore, there is still a high demand for therapies with a similar efficacy profile to current therapies but a better safety profile and a more patient-friendly RoA. Oral classes, such as
JAKi and the upcoming
BTKi, are expected to contribute to the rheumatoid arthritis market growth due to patient-friendly RoA.
However, several factors are likely to hamper the rheumatoid arthritis market growth. The rheumatoid arthritis market is
highly competitive, and new entrants are expected to face some resistance and low uptake because anti-TNFs currently dominate the rheumatoid arthritis market, and the
entry of biosimilars will pose significant challenges to new and upcoming treatment options in the rheumatoid arthritis market.
In addition, the entry of biosimilars has already begun in the US and EU (i.e.,
Remicade biosimilars), and as a result,
sales value has started to decline. The impact will be more pronounced when biosimilars/ generics of some blockbuster drugs, such as
Humira (i.e., 2023 in the US),
Xeljanz (i.e., 2025 in the US), will enter the rheumatoid arthritis market, and this will significantly impact the growth of the rheumatoid arthritis market.
Scope of the
Rheumatoid Arthritis
Market Report
Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies
Rheumatoid Arthritis
Market Dynamics: Rheumatoid Arthritis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement
Discover more about rheumatoid arthritis drugs in development @
Rheumatoid Arthritis Clinical Trials
Table of Contents
Related Reports
Rheumatoid Arthritis Epidemiology Forecast
Rheumatoid Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Juvenile Rheumatoid Arthritis Pipeline
Juvenile Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including
Juvenile Rheumatoid Arthritis Market
Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including
Psoriatic Arthritis Pipeline
Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including
Mylan, Celltrion, Pfizer, Amgen, among others.
Psoriatic Arthritis Market
Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including
Mylan, Celltrion, Pfizer, Amgen, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market
Related Healthcare Blogs
Rheumatoid Arthritis Emerging Drugs
Knee Osteoarthritis Pipeline
Rheumatoid Arthritis Market Scenario
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Additionally, get in touch with our business executive to explore @
Healthcare Due Diligence Services
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。